Although leukemia does not necessarily undergo EMT, E-cadherin expression is reduced by hypermethylation of the E-cadherin gene promoter (90, 91), while VE-cadherin and N-cadherin expression contributes to chemoresistance in BCR-ABL+ (Ph+) ALL and CML (92, 93). The gene discussed is CDH1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.